Focused On-demand Library for Palmitoyltransferase ZDHHC20

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q5W0Z9

UPID:
ZDH20_HUMAN

ALTERNATIVE NAMES:
Acyltransferase ZDHHC20; DHHC domain-containing cysteine-rich protein 20; Zinc finger DHHC domain-containing protein 20

ALTERNATIVE UPACC:
Q5W0Z9; A8MTV9; C9JG20; I6L9D4; Q2TB82; Q6NVU8

BACKGROUND:
The enzyme Palmitoyltransferase ZDHHC20, known for its palmitoylation activity, is pivotal in cellular signaling and viral protein maturation. It catalyzes the palmitoylation of EGFR, affecting signal duration and degradation. ZDHHC20 prefers C16 acyl-CoA but can work with C14 and C18 chains. Additionally, it plays a significant role in the lipidation of the SARS-CoV-2 spike protein, enhancing virus fusion with target cells.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Palmitoyltransferase ZDHHC20 offers promising avenues for developing new therapeutic approaches. Its critical role in EGFR signaling and viral protein processing positions it as a valuable target for designing innovative cancer and antiviral therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8641 of 8789